Georg Pirmin Meyer

Corporate Officer/Principal chez NUVALENT, INC.

Consumer Services

Health Technology

Distribution Services

Profil

Georg Pirmin Meyer is Chief International Officer at Nuvalent, Inc. since 2026.
Former positions include Co-Managing Director at Vertex Pharmaceuticals (Germany) GmbH and SVP & General Manager-International at Blueprint Medicines Corp.
Education includes doctorates from the University of Freiburg and the University of Innsbruck.

Postes actifs de Georg Pirmin Meyer

Sociétés	Poste	Début
NUVALENT, INC.	Corporate Officer/Principal	27/05/2026

Tous les postes actifs de Georg Pirmin Meyer

Anciens postes connus de Georg Pirmin Meyer

Sociétés	Poste	Fin
BLUEPRINT MEDICINES CORPORATION	Corporate Officer/Principal	-
Vertex Pharmaceuticals (Germany) GmbH Vertex Pharmaceuticals (Germany) GmbH Medical DistributorsDistribution Services Wholesales pharmaceutical products	Directeur Général	-

Voir l'expérience en détail de Georg Pirmin Meyer

Formation de Georg Pirmin Meyer

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Georg Pirmin Meyer

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	5
University of Freiburg University of Freiburg Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Innsbruck University of Innsbruck Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Blueprint Medicines Corp. Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer	Health Technology
Vertex Pharmaceuticals (Germany) GmbH Vertex Pharmaceuticals (Germany) GmbH Medical DistributorsDistribution Services Wholesales pharmaceutical products	Distribution Services
Nuvalent, Inc. Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer	Health Technology